In the Seroquel case, Faruqi & Faruqi represents a proposed class of direct purchasers of AstraZeneca’s Seroquel XR, a prescription drug treatment for schizophrenia, bipolar disorder, and depression. The complaint alleges that AstraZeneca entered into reverse payment agreements with Handa Pharmaceuticals and Accord Pharmaceuticals that induced the two generic manufacturers to delay launching their generic versions of Seroquel XR.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 08/02/2019
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn email@example.com Phone (215) 277-5770 Fax (215) 277-5771